Abstract
Betaine supplementation in humans has been shown to lower plasma homocysteine concentrations in modestly hyperhomocysteinemic patients. Betaine treatment is associated with increased plasma low-density-lipoprotein (LDL) cholesterol, suggesting that although betaine supplementation lowers homocysteine, a risk factor for cardiovascular disease, changes in blood lipids may have a counterbalancing effect. However, whether the betaine effect on LDL concentration is a clinically significant problem that should change treatment options or is simply an artifact needs further study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
